ReviewNeurology2026
Legal Protections to Mitigate Discrimination due to Neurodegenerative Biomarker Status.
Review in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is a critical time to advance solutions that would mitigate the perceived, potential, and actual risk of discrimination based on neurodegenerative biomarker information. Across neurodegenerative conditions, biomarkers are being evaluated to detect disease pathology before the onset of clinically measurable symptoms. Clinical adoption and research that expands the use of biomarkers raises novel legal questions and exposes potential gaps in existing privacy and antidiscrimination laws. These concerns may be particularly salient for individuals in the earliest disease stages who may still be employed, have yet to complete financial or medico-legal planning (e.g., life insurance), or are considering housing changes. In this article, we evaluate the current landscape of legal protections and propose a strategy for developing a policy agenda that is informed by empirical evidence. We propose an iterative approach that begins with a comprehensive evaluation of the existing landscape of legal protection alongside the development of evidence that identifies priorities and informs policy strategies. Our recommendations aim to build from existing legal mechanisms, identify gaps in legal protections, and prioritize future policy goals that stem from perceived and actual privacy and discrimination risks. We argue that it is essential to understand the goals of new legislative efforts, to comprehensively assess what evidence is needed to prioritize specific domains of discrimination, and to consider unintended consequences of legislative approaches. Absent this, we risk enshrining lackluster protections into law that fail to support access to biomarker testing advancements that align with patient and participants' interests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.